Market Overview

Global Stereotactic Surgery Devices (Gamma Knife, Linear Accelerator, CyberKnife, Proton Beam Therapy) Market 2018 - 2025 - ResearchAndMarkets.com

Share:

The "Stereotactic
Surgery Devices Market Size, Share & Trends Analysis Report By Type
(Gamma Knife, Linear Accelerator, CyberKnife, Proton Beam Therapy), By
Region, And Segment Forecasts, 2018 - 2025"
report has been
added to ResearchAndMarkets.com's offering.

The global stereotactic surgery devices market size is expected to reach
USD 25.9 billion by 2025, expanding at a CAGR of 6.1% during the
forecast period.

Stereotactic surgery is a minimally invasive alternative for traditional
invasive ablation and biopsy methods. Since, stereotactic surgery has
various advantages such as higher efficacy, minimal or no surgical
incisions, and lower risk of damage to healthy cells, it is replacing
conventional radiotherapies. These surgical procedures have helped
overcome drawbacks associated with traditional invasive surgeries, such
as destruction of healthy cells and higher risk of recurrence &
postoperative complications.

Only around 10.0% of the population in low and middle-income countries
have access to radiation therapy, owing to dearth of radiation therapy
devices. A market leader, Elekta, in its 2016 annual report stated that
the number of installations of linear accelerators in high-income
countries was approximately 13,000, whereas the requirement was around
25,000. Hence, huge demand-supply discrepancy of radiotherapy devices is
likely to open new avenues for major market players in developing
countries.

Some of the major players operating in the market are Siemens Ag, Elekta
AB, Varian Medical Systems, IBA, and Accuray Incorporated

Key Topics Covered:

Chapter 1 Report Scope

Chapter 2 Research Methodology

Chapter 3 Objective

Chapter 4 Executive Summary

Chapter 5 Market Definitions

Chapter 6 Industry Outlook

Chapter 7 Stereotactic Surgery Devices Market: Product Estimates & Trend
Analysis

Chapter 8 Stereotactic Surgery Devices Market: Regional Estimates &
Trend Analysis, by Product Type

Chapter 9 Competitive Landscape

  • AstraZeneca
  • Bayer AG
  • Merck KGaA
  • Abbott
  • Pfizer, Inc.
  • Sanofi
  • Bristol Myers Squibb Company
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Ferring B.V.

For more information about this report visit https://www.researchandmarkets.com/research/c2vj9f/global?w=4

View Comments and Join the Discussion!